Management Research Insulin Therapy Insulin Pediatric Diabetes Impact on Families Advocacy Type 2 Diabetes Autoimmune Diabetes Awareness Campaigns Childhood Diabetes Symptoms Stem Cell Therapy Diagnosis Treatment Methods Awareness Awareness and Advocacy Youth Diabetes Awareness Teplizumab Genetic Factors Non-Autoimmune Type 1 Diabetes Autoimmune Disorders Cardiovascular Disease Parental Influence Autoimmune Disease Research on Treatments Diabetic Ketoacidosis Beta-cell Function Charity Support Systems Management Strategies Beta Cell Function Non-autoimmune Diabetes Baricitinib Child Health Treatment Options Treatment Strategies Adult-Onset Type 1 Diabetes Sub-Saharan Africa
The oral JAK inhibitor preserved beta‑cell function during 48 weeks of use, prompting plans for larger Phase III studies.